(New York, USA) DelveInsight’s ‘Crohn’s Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Crohn’s Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Crohn’s Disease pipeline domain.
For Crohn’s Disease emerging drugs, the Crohn’s Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Crohn’s Disease Pipeline Report
- DelveInsight’s Crohn’s Disease Pipeline analysis depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
- The leading Crohn’s Disease companies include Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others are evaluating their lead assets to improve the Crohn’s Disease treatment landscape.
- Key Crohn’s Disease pipeline therapies in various stages of development include Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others.
- In May 2023, Rinvoq (upadacitinib) has been approved by the FDA for individuals with moderate to severe active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first FDA-approved oral medication for the treatment of moderately to highly active Crohn’s disease.
- In February 2023, Janssen collaborated with Eli Lilly to address the lack of pediatric therapies for Crohn’s Disease. The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources to accelerate the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
- In February 2023, Agomab Therapeutics reported positive data from its Phase I study of AGMB-129 to treat Fibrostenosing Crohn’s Disease (FSCD). The trial was designed for assessing the tolerability, pharmacokinetics (PK), and safety of the oral, gastrointestinal (GI)-restricted, small molecule kinase ALK5 (TGFbRI or ALK5) inhibitor AGMB-129 in healthy participants. TGFb is a known master fibrosis regulator.
Request a sample and discover the recent breakthroughs happening in the Crohn’s Disease pipeline landscape @ Crohn’s Disease Pipeline Outlook
Crohn’s Disease Overview
Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. Named after Dr. Burrill B. Crohn, who first described the disease in 1932, Crohn’s disease belongs to a group of conditions known as inflammatory bowel diseases (IBD), which also includes ulcerative colitis. The exact cause of Crohn’s disease is unknown, but it is believed to involve a combination of genetic, environmental, and immune system factors. Symptoms of Crohn’s disease can vary from person to person and may include abdominal pain, diarrhea, rectal bleeding, weight loss, fatigue, and malnutrition. The severity of symptoms can also fluctuate over time, with periods of remission and periods of flare-ups. In some cases, Crohn’s disease can also cause complications such as strictures, fistulas, abscesses, and bowel obstructions.
Diagnosing Crohn’s disease typically involves a combination of medical history evaluation, physical examination, laboratory tests, and imaging studies such as endoscopy, colonoscopy, and imaging scans. There is no cure for Crohn’s disease, and the primary goal of treatment is to control inflammation, manage symptoms, and achieve and maintain remission. Treatment options for Crohn’s disease include medications, lifestyle changes, and, in some cases, surgery. Medications commonly prescribed for Crohn’s disease include anti-inflammatory drugs, immune system suppressors, antibiotics, and biological therapies.
Find out more about Crohn’s Disease medication @ New Drug for Crohn’s Disease
Crohn’s Disease Treatment Analysis: Drug Profile
Guselkumab: Janssen
Guselkumab is a human immunoglobulin G1 lambda (IgG1) monoclonal antibody that inhibits interleukin-23 specifically. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway, mediating the inflammatory cascade that leads to the production of psoriatic plaques. Guselkumab indicated enhanced skin clearance and symptomatic improvements in dermatological symptoms of psoriasis in clinical trials. The clinical trial is currently in Phase III.
RHB-104: RedHill Biopharma
RHB-104 is a potentially game-changing, patented experimental medication in the form of an oral capsule with powerful intracellular, antimycobacterial, and anti-inflammatory capabilities. The clinical trial is currently in Phase III.
Key Crohn’s Disease Therapies and Companies
- Guselkumab: Janssen
- RHB-104: RedHill Biopharma
- Filgotinib: Galapagos/Gilead Sciences
- Mirikizumab: Eli Lilly and Company
- Ozanimod: Celgene Corporation
- Brazikumab: AstraZeneca
- Etrolizumab: Roche
Learn more about the novel and emerging Crohn’s Disease pipeline therapies @ Crohn’s Disease Clinical Trials
Crohn’s Disease Therapeutics Assessment
- By Product Type
-
- Monotherapy
- Combination Therapy
- By Stage
-
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Crohn’s Disease Pipeline Report
- Coverage: Global
- Key Crohn’s Disease Companies: Janssen, RedHill Biopharma, Amgen, Pfizer, Prometheus Biosciences, AgomAb Therapeutics, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, HAV Vaccines Ltd, Enzo Biochem Inc., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Pfizer, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Pfizer, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Janssen, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Celularity, Cerecor, GlaxoSmithKline, KangStem Biotech, Immunic, Alpha Cancer Technologies, Koutif Therapeutics, Tract Therapeutics, Trio medicines, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, JHL Biotech, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, AbbVie, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Engitix, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Assembly Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo, and others.
- Key Crohn’s Disease Pipeline Therapies: Guselkumab, ABP-654, RHB-104, Etrolizumab, PRA-023, AGMB-129, Filgotinib, Mirikizumab, Ozanimod, Brazikumab, Remestemcel-L, Rifaximin, Foralumab, ABX-464, Etrasimod, CYTO-201, Masitinib, HAV anti-MAP vaccine, Alequel, Cannabidiol, SHR0302, QBECO-SSI, PRV-6527, PF-06651600, MT-1303, TAK-018, SGX203, IMU 838, Alicaforsen, Bacteroides thetaiotaomicron, BT-11, JNJ-64304500, E6011, BMS-986165, Spesolimab, Aldesleukin, CBP-307, TD-1473, JKB-122, PDA-001, MDGN-002, GSK1070806, Furestem-CD, IMU-856, ACT-101, KT-1002, TregCel, TR8, CCX507, NP-178, NeuLara, JHL1255, Anti-inflammatory drug LIS, Brilacidin, Research programme: anti-fibrotic therapeutics Faecalibacterium Prausnitzii, Navitoclax, Research programme: Crohn’s disease therapeutics, AK 101, IBD Program, MAK 11049, GI restricted TGF-β inhibitor, Research programme: mannose receptor-targeted therapeutic agents, Research programme: haematopoietic stem cell based ex vivo gene therapy, Xcimzane, TP317, TEM1657, SYGN 313, SYNB 8802, MORF 057, IBD Program, CU06, MSC1 & MSC2, Phospholipid A2 (PLA2), CKD-506, Implantable cell therapies, Neuregulin-4 (NRG-4), ABBV-154, AIB-301, ATI-2138 ITK/TXK/JAK3 Inhibitor, JAK1/JAK3 Inhibitor, ITK/TXK/JAK3 Inhibitor, ATH-105, ATH-63, DNL975, CrohnArt, and others.
Dive deep into rich insights for drugs used for Crohn’s Disease treatment; visit @ Crohn’s Disease Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Crohn’s Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Crohn’s Disease Pipeline Therapeutics |
| 6. | Crohn’s Disease Pipeline: Late Stage Products (Phase III) |
| 7. | Crohn’s Disease Pipeline: Late Stage Products (Phase III) |
| 8. | Crohn’s Disease Pipeline: Mid-Stage Products (Phase II) |
| 9. | Crohn’s Disease Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Crohn’s Disease therapy in the pipeline, reach out @ Crohn’s Disease Medication
Related Reports
Crohn’s Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Crohn’s disease epidemiology trends.
Crohn’s Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn’s disease companies, including Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Amgen, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., among others.
Irritable Bowel Syndrome Market
Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Pipeline
Irritable Bowel Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.
Irritable Bowel Syndrome Epidemiology Forecast
Irritable Bowel Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the irritable bowel syndrome epidemiology trends.
Other Trending Reports
Bronchial Spasm Market | Meningioma Market | Necrotizing Enterocolitis Market Hyperhidrosis Market |Bacterial Meningitis Market | Anaphylaxis Market | Neurostimulation Devices Market | Intracranial Pressure Monitoring Devices Market | Acute Pharyngitis Market | Hepatitis B Virus Market | Thymic Carcinoma Market | Bladder Cancer Market | Spasticity Market | Interbody Cages Market | Helicobacter Pylori Infection Market | Intravenous Immunoglobulin Market | Opioid Induced Constipation Market | Ophthalmic Imaging Equipment Market | Epilepsy Market | Pharmaceutical Consulting Companies | Acquired Immunodeficiency Syndrome Market | Image Guided Surgery Devices Market | Androgenetic Alopecia Market | Acute Lung Injury Market | Astigmatism Market | Familial Primary Pulmonary Hypertension Market | Progressive Multifocal Leukoencephalopathy Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187